Cargando…
Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
Breast cancer (BC) is the most common cause of cancer-related death in women worldwide. Therapies targeting molecular pathways altered in BC had significantly enhanced treatment options for BC over the last decades, which ultimately improved the lives of millions of women worldwide. Among various mo...
Autores principales: | Sobhani, Navid, Fassl, Anne, Mondani, Giuseppina, Generali, Daniele, Otto, Tobias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912842/ https://www.ncbi.nlm.nih.gov/pubmed/33535617 http://dx.doi.org/10.3390/cells10020293 |
Ejemplares similares
-
Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2019) -
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
por: Formisano, Luigi, et al.
Publicado: (2019) -
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
por: Corona, Silvia Paola, et al.
Publicado: (2018) -
Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study
por: D’Angelo, Alberto, et al.
Publicado: (2022) -
Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma
por: Sobhani, Navid, et al.
Publicado: (2017)